Taro AMAGASAKI | Novartis, Basel | Novartis Oncology
网页Taro AMAGASAKI | Cited by 254 | of Novartis, Basel | Read 15 publications | Contact Taro AMAGASAKI.
Taro Amagasaki - Head of Analytics and Clinical Development …
网页Nuclear Medicine MD needed to join the Radioligand Therapy Clinical Development team at Novartis Oncology! #helenodonovan #nuclearmedicine…. Taro Amagasaki さんが「いいね！. 」しました. I am so pleased to...
- 职位: Novartis - Executive Director, …
- 位置: 374人のフォロワー
A phase I study of single-agent BEZ235 special delivery system …
网页2018年11月16日 · This study evaluated the safety and tolerability of BEZ235 doses from 400 mg to 1400 mg in Japanese patients with solid tumors. Each one out of six evaluable patients experienced DLTs of grade 2 allergic reaction at the 1200 mg dose level and grade 4 thrombocytopenia at the 1400 mg dose level.
A phase I study of single-agent BEZ235 special delivery system
网页PMID: 30446785. PMCID: PMC6394493. DOI: 10.1007/s00280-018-3725-2. Abstract. Purpose: BEZ235 is a dual kinase inhibitor of phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin, which are key components of the PI3K pathway.
Safety and Pharmacokinetics of Ruxolitinib (INC424) in Healthy …
网页2011年11月18日 · Ruxolitinib (INC424), a potent and selective oral JAK1 and JAK2 inhibitor, demonstrated rapid and durable reductions in splenomegaly and improved disease-related symptoms, role functioning, and quality of life (QoL) in 2 phase 3 studies in patients with myelofibrosis (MF) (the COMFORT studies).
Assessing the Safety and Efficacy of Ruxolitinib in a Multicenter, …
网页2015年12月3日 · BACKGROUND: Ruxolitinib is a potent and selective JAK1/JAK2 inhibitor that has demonstrated durable improvements in splenomegaly and MF-related symptoms, and has been associated with improved overall survival in patients (pts) with MF in randomized clinical trials. Results from the phase 2 Asian multinational study (NCT01392443) supported these ...
Assessing the Safety and Efficacy of Ruxolitinib in a Multicenter, …
网页2015年12月3日 · BACKGROUND: Ruxolitinib is a potent and selective JAK1/JAK2 inhibitor that has demonstrated durable improvements in splenomegaly and MF-related symptoms, and has been associated with improved overall survival in patients (pts) with MF in randomized clinical trials.
Safety and Pharmacokinetics of Ruxolitinib (INC424) in
网页2011年11月18日 · Ruxolitinib (INC424), a potent and selective oral JAK1 and JAK2 inhibitor, demonstrated rapid and durable reductions in splenomegaly and improved disease-related symptoms, role functioning, and quality of life (QoL) in 2 phase 3 studies in patients with myelofibrosis (MF) (the COMFORT studies).
Efficacy and safety of omalizumab in an Asian population with …
网页Data indicate that the efficacy of add-on omalizumab in patients with moderate-to-severe allergic asthma is accompanied by an acceptable safety profile and was independent of duration of treatment, age, severity of asthma, and risk of bias. Expand. 257.
Efficacy and safety of nilotinib in Japanese patients with imatinib ...
网页2012年2月23日 · Taro Amagasaki, Aira Wanajo & Tomoki Naoe. 1094 Accesses. 16 Citations. Explore all metrics. Abstract. Although the tyrosine kinase inhibitor (TKI) imatinib is often used as first-line therapy for newly diagnosed chronic myelogenous leukemia (CML), some patients fail to respond, or become intolerant to imatinib.